Skip to content

Effect of Vitamin D Supplementation on Coronary Calcification and Parathyroid Hormone in CKD Patients

Effect of Vitamin D Supplementation on Coronary Calcification and Parathyroid Hormone in CKD Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01672047
Acronym
EVIDENCE
Enrollment
350
Registered
2012-08-24
Start date
2012-04-30
Completion date
2015-12-31
Last updated
2012-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Vitamin D Deficiency

Keywords

The 25(OH) vitamin D level, The 1.25(OH) vitamin D level, The intact PTH level, The calcification score of coronary artery, The microalbuminuria level

Brief summary

The investigators hypothesize that the chronic kidney disease patients who suffer from vitamin D deficiency will be benefit from given Vitamin D2 because coronary artery calcification and hyperparathyroidism will be improved.

Detailed description

We will call for 350 CKD patients (250 CKD3-5stage and 100 CKD5D stage)who suffer from vitamin D deficiency.They will be divided into 2 groups. One group will be given vitamin D and the other will not. They will take coronary artery CT test every year(in 2 years).We will compare the coronary calcification progression between the 2 groups.

Interventions

25(OH)D level \<12 nmol/L 50000IU/weekX12week, 12-39 nmol/L 50000IU/weekX4week then,50000IU/month, 40-75 nmol/L 50000IU/month, 75-116.75nmol/L 25000IU/month, \>116.75nmol/L stopped.

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* chronic kidney disease patients (3-5D) * serum 25(OH)D \< 40nmol/L(16ng/ml),serum calcium \< 2.55mmol/L(10.2mg/dL); * willing to sign * could obey the follow up design

Exclusion criteria

* allergy to vitamin D * heart failure (NYHA more than 2 grade) * pregnant * malignant tumor * critical hepatic disease * taking Vitamin D or analogue in 3 recent months * taking other clinical trial

Design outcomes

Primary

MeasureTime frameDescription
the improvement of coronary artery calcification2 yearsWe use CT to detect the coronary artery calcification score in the chronic kidney disease patients for 3 times (baseline, 12 month and 24 month). We will compare the 2 arms (treatment or not)to know if there is any difference。

Secondary

MeasureTime frameDescription
the improvement of proteinuria2 yearsWe detect the microalbuminuria in the chronic kidney disease patients for 5 times (baseline, 6 month,12 month 18month and 24 month). We will compare the 2 arms (treatment or not)to know if there is any difference。

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026